Sign Out
In patients with intravascular volume depletion; for such, patients who treated with diuretics, restriction of sodium intake, diarrhea or vomiting, hypotension may occur. Correct these conditions prior to administration under close medical care and dose reduction.
As a consequence of inhibiting the renin-angiotensin-aldosterone system, Irbesartan may lead to renal artery stenosis resulting in severe hypotension and renal insufficiency.
When the drug is used in patients with impaired renal function and kidney transplantation, a frequent monitoring of potassium and creatinine level is recommended.
The drug is not recommended to use in patients with primary aldosteronism due to the renin-angiotensin-aldosterone effect.
As the renin-angiotensin-aldosterone effect, Irbesartan may increase serum potassium level, especially in renal impairment or heart failure. Close monitoring of serum potassium in patients at risk is advised.
The drug should be used with caution in patients with aortic, mitral valve stenosis and obstructive hypertrophic cardiomyopathy.
Angiotensin antagonists are apparently less effective in lowering blood pressure in black people than in non-blacks, possibly because of low renin states in this population.
